Results 251 to 260 of about 435,388 (276)

Cancer stem cells release interleukin-33 within large oncosomes to promote immunosuppressive differentiation of macrophage precursors. [PDF]

Immunity
Erickson HL, Taniguchi S, Raman A, Leitenberger JJ, Malhotra SV, Oshimori N.   +5 more
europepmc   +1 more source

Iron/Cobalt Dual‐Atom Catalyst Orchestrate Photothermal‐Chemodynamic Immunotherapy Against MRSA: Multi‐Omics Dissection in Murine and Porcine Models

Advanced Science, EarlyView.
FeCo dual‐atom catalyst (FeCo‐N‐DAC) with ultrahigh metal loading (Fe > 5.4%, Co > 4.8%) is developed for synergistic photothermal‐chemodynamic immunotherapy. FeCo‐N‐DAC penetrates deep‐seated tissues, eradicates MRSA biofilms, and reprograms immune‐inflammatory pathways via multi‐omics‐validated mechanisms.
Shihao Xu, Binge Huang, Hao Lin, Jinming Li, Zhaoxiang Lu, Qi Zhang, Jia Li, Shiping Yang, Songsong Lan, Yan Yang, Yun Feng, Xiaojun He   +11 more
wiley   +1 more source

P2X7 Receptor-Induced Human Mast Cell Degranulation Is Enhanced by Interleukin 33. [PDF]

Int J Mol Sci
Salcman B, Bahri R, West PW, Tontini C, Affleck K, Bulfone-Paus S.   +5 more
europepmc   +1 more source

Core Fucosylation Represses SMURF1‐Dependent Degradation of CD47 to Promote Tumor Immune Evasion

Advanced Science, EarlyView.
FUT8‐mediated core fucosylation of CD47 at N111 blocks SMURF1 binding and reduces CD47 ubiquitination and degradation. Blocking N111 glycosylation reduces CD47 expression and promotes macrophage phagocytosis of tumor cells. Furthermore, ablating CD47 core fucosylation boosts CD103+ dendritic cells (DCs) infiltration, increases natural killer (NK) cell ...
Yuting Cao, Siyuan Chai, Mingyang Li, Xiaoming Chen, Jiating Hu, Bingyi Lin, Liming Wu, Wen Yi, Qiang Zhu   +8 more
wiley   +1 more source

Activation of interleukin 33-NFκB axis in granulosa cells during atresia and its role in disposal of atretic follicles†. [PDF]

Biol Reprod
Wu J, Carlock C, Tatum K, Shim J, Zhou C, Lou Y.   +5 more
europepmc   +1 more source

Circulating interleukin-33 levels in obesity and type 2 diabetes: a systematic review and meta-analysis.

Am J Physiol Endocrinol Metab
Missous G, Van Panhuys N.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interleukin-33 in health and disease

Nature Reviews Immunology, 2016
Interleukin-33 (IL-33) - a member of the IL-1 family - was originally described as an inducer of type 2 immune responses, activating T helper 2 (TH2) cells and mast cells. Now, evidence is accumulating that IL-33 also potently stimulates group 2 innate lymphoid cells (ILC2s), regulatory T (Treg) cells, TH1 cells, CD8+ T cells and natural killer (NK ...
Foo Yew, Liew, Jean-Philippe, Girard, Heth Roderick, Turnquist   +2 more
openaire   +2 more sources

Interleukin-33: increasing role in dermatological conditions

Archives of Dermatological Research, 2016
Interleukin-33 is a novel and an unconventional member of IL-1 family. It is an inflammation-induced factor with dual function exercising its role as an intracellular regulator of gene expression, as well as, an extracellular alarm mediator. It is a ligand for ST2, a heterodimeric membrane-bound receptor of the orphan IL-1 family receptor.
Balato, Anna, Raimondo, Annunziata, Balato, Nicola, Ayala, Fabio, LEMBO, Serena   +4 more
openaire   +5 more sources

Interleukin-33 in atopic dermatitis

Journal of Dermatological Science, 2019
Atopic dermatitis (AD) is characterized by pruritus, barrier disruption, and inflammationincluding type 2 cytokine production. Interleukin-33 (IL-33) is an inflammatory cytokine that is over-expressed in the keratinocytes of patients with AD. IL-33 transgenic mice, which express IL-33 specifically in keratinocytes, spontaneously develop AD-like eczema,
openaire   +2 more sources